| Somatotropin deficiency
Skytrofa vs Sogroya
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Skytrofa vs Sogroya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSogroya has a higher rate of injection site reactions vs Skytrofa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sogroya but not Skytrofa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skytrofa
Sogroya
At A Glance
SC injection
Once weekly
Pegylated growth hormone prodrug
SC injection
Once weekly
Growth hormone analog
Indications
- Somatotropin deficiency
- Somatotropin deficiency
- Noonan Syndrome
Dosing
Somatotropin deficiency (pediatric) 0.24 mg/kg body weight SC once weekly; individualize and titrate based on response.
Somatotropin deficiency (adult) Starting dose 0.7-2.1 mg SC once weekly based on age and concomitant oral estrogen use; titrate monthly based on clinical response and/or IGF-1 concentration; maximum 6.3 mg once weekly.
Somatotropin deficiency (pediatric) 0.16 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Noonan Syndrome, SGA, ISS 0.24 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Somatotropin deficiency (adult) Initiate 1.5 mg SC once weekly; titrate every 2-4 weeks by 0.5-1.5 mg to desired response; maximum 8 mg once weekly.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatropin or any excipient in SKYTROFA
- Closed epiphyses in pediatric patients
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
- Acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somapacitan-beco or any excipient
- Pediatric patients with closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Adverse Reactions
Most common (>= 5%) Viral infection, pyrexia, cough, nausea and vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia and arthritis (pediatric); edema, central hypothyroidism (adult)
Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in Prader-Willi syndrome pediatric patients
Postmarketing Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema, osteonecrosis in pediatric patients
Most common (>=5%) Nasopharyngitis, respiratory tract infection, pyrexia, headache, pain in extremity, injection site reaction, diarrhea, vomiting, cough, ear infection
Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasm risk, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipohypertrophy/lipoatrophy, sudden death in Prader-Willi syndrome patients
Postmarketing Osteonecrosis in pediatric patients
Pharmacology
Lonapegsomatropin-tcgd is a pegylated prodrug of somatropin that releases active growth hormone via autocleavage of the TransCon linker; somatropin binds the growth hormone (GH) receptor, driving IGF-1-mediated and direct effects including chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal growth at the epiphyses of long bones.
Somapacitan-beco is a human growth hormone (hGH) analog that binds to a dimeric GH receptor in the cell membrane of target cells, triggering intracellular signal transduction and pharmacodynamic effects mediated both directly and through IGF-1 produced in the liver.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skytrofa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Sogroya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Skytrofa
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Sogroya
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Skytrofa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Sogroya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
A·S·A·P Co-pay Program: SkytrofaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Sogroya.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkytrofaView full Skytrofa profile
SogroyaView full Sogroya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.